Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111565 · Otsuka Pharmaceutical Development & Commercialization, Inc. · PHASE3 · terminated · last registry update 2021-12-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.” | – | Registry record, Otsuka Pharmaceutical Development & Commercialization, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-11-02Phase 3 first posted: Dr. Inge Winter, Clozapine + Esketamine Nasal Product (NCT05603104)
- 2022-09-30Results posted on the registry: University of Toledo Health Science Campus, Fluoxetine (NCT04377308)
- 2022-08-29Phase 3 first posted: University of Michigan, Lexapro (NCT05519683)
- 2022-08-16Results posted on the registry: Janssen Research & Development, LLC, JNJ-42847922 + Placebo Matching to JNJ-42847922 (NCT03321526)
- 2022-05-24Results posted on the registry: Janssen Research & Development, LLC, Esketamine 56 mg + Esketamine 84 mg (NCT03434041)
- 2022-05-24Results posted on the registry: Washington University School of Medicine, Aripiprazole Augmentation + Bupropion Augmentation (NCT02960763)
- 2021-09-29Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone (NCT05061719)
- 2021-09-29Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone + Placebo (NCT05061706)
- 2021-08-02Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone + Placebo (NCT04985942)
- 2021-07-22Phase 3 first posted: New York State Psychiatric Institute, Venlafaxine HCl ER (NCT04973930)
- 2021-07-12Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone 42 mg + Placebo (NCT04959032)
- 2021-04-01Results posted on the registry: New York State Psychiatric Institute, Fluoxetine + Citalopram (NCT02473250)
- 2021-03-29Results posted on the registry: University of Texas Southwestern Medical Center, Naltrexone: Vivitrol® + Placebo (PLB) Injectable (NCT03078075)
- 2021-02-18Phase 3 first posted: Children's Hospital Los Angeles, Fluoxetine (NCT04760275)
- 2021-01-27Phase 3 first posted: Cardresearch, Budesonide Powder + Fluoxetine 20 MG (NCT04727424)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision